BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BioAge Labs, Inc.

BioAge Labs, Inc.

BIOA

0.00

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ: BIOA) with a Buy and maintains $40 price target.